Skip to main content

Market Overview

Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings

Share:
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
  • The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China.
  • The trial will evaluate the safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
  • ATG-019 is a dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc (NASDAQ: KPTI).
  • Antengene reached an exclusive agreement with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in Greater China, South Korea, Australia, New Zealand, and ASEAN countries.
  • Antengene is conducting a Phase 1 trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and is planning to conduct clinical trials exploring its combination potential with other agents.
  • Price Action: KPTI shares are up 4.95% at $11.66 in the premarket session on the last check Tuesday.
 

Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: Briefs cancerBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com